Business Wire

New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...
Yahoo Finance

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Business Wire

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...
Yahoo Finance

New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to ...

Basel, 12 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new clinical and real-world data for OCREVUS® (ocrelizumab), demonstrating its role in continuing to transform care for ...
WebMD

Your Guide to Ocrevus and Ocrevus Zunovo for Multiple Sclerosis (MS)

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
PharmiWeb

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s ...
CBS News

FDA approves first drug for aggressive multiple sclerosis

A new multiple sclerosis drug approved by the U.S. Food and Drug Administration late Tuesday offers hope to patients with the most severe form of the progressive disease. The intravenous drug, made by ...
Monthly Prescribing Reference

SC-Administered Ocrevus Zunovo Approved for Multiple Sclerosis

Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab, a ...
Healthline

Ocrevus Interactions: Alcohol, Medications, and Others

Ocrevus (ocrelizumab) has potential interactions with other medications and some vaccines. These interactions could affect how well the drug works or cause harmful effects. Ocrevus is used in adults ...
Monthly Prescribing Reference

Ocrevus Zunovo

Ocrelizumab 920mg, hyaluronidase-ocsq 23000 Units; per 23mL; soln for SC inj; preservative-free. Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do ...
PharmiWeb

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's office This approval is backed by a decade of proven ...